VYNE Form 4: 3,420 Shares Withheld at $0.335 by CFO

VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025.

Rhea-AI Filing Summary

VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025. The filing shows 3,420 shares of common stock were disposed of at a price of $0.335 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the reporting person beneficially owns 111,653 shares, held in a direct ownership form. The Form 4 is signed by an attorney‑in‑fact and contains no other transactions or derivative instruments.

Insider Trade Summary

Exercise Price or Tax Liability: 3,420 shares

Exercise Price or Tax Liability 1 txn

Insider Zeronda Tyler

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,420	$0.335	$1K

Holdings After Transaction: Common Stock — 111,653 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the VYNE (VYNE) Form 4 filed by Zeronda Tyler report?

The Form 4 reports a 9/30/2025 disposition of 3,420 common shares at $0.335 per share, withheld to satisfy tax obligations from RSU vesting.

Who is the reporting person on the Form 4 for VYNE?

The reporting person is Zeronda Tyler, identified as the company's Chief Financial Officer.

How many VYNE shares does the reporting person own after the transaction?

After the transaction, the reporting person beneficially owns 111,653 shares, held directly.

Why were the 3,420 VYNE shares disposed of according to the filing?

The filing states the shares were withheld by the issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Were any derivative securities reported in this Form 4 for VYNE?

No derivative securities (options, warrants, convertible instruments) are reported in the Form 4; only a non‑derivative common stock disposition is shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 05:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Zeronda Tyler

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

685 ROUTE 202/206 N, SUITE 301

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F(1)		3,420	D	$0.335	111,653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

	/s/ Mutya Harsch, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.